GlobeNewswire

Banks net position in the Riksbank

Share
SEP 13, 2019  
SEK MILLION  
   
LENDING BORROWING
261  

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma21.1.2020 07:00:00 CETPress release

Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse large B-cell lymphoma ·Polivy approval is based on a phase Ib/II study, the first and only study showing improved response rates and overall survival in patients with this aggressive lymphoma who are not candidates for a haematopoietic stem cell transplant, compared to a commonly used regimen Basel, 21 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant. “With this approval, people in the EU with relapsed or refra

SEB: Nordic Outlook: Kortsiktig lättnad men långsiktiga risker21.1.2020 07:00:00 CETPressemelding

Pressmeddelande Stockholm 21 januari 2020 Nordic Outlook: Kortsiktig lättnad men långsiktiga risker Sverige: Tillväxt under trend – stigande arbetslöshet och räntepaus Världsekonomin ser ut att ha stått emot fjolårets industrisvacka. Tillväxten växlar upp försiktigt men kvarstående politisk osäkerhet och utbudsrestriktioner dämpar kraften i uppgången. Central­bankssignaler om låga räntor under lång tid ger stöd men reser också frågor kring långsiktiga risker med skulduppbyggnad och upptrissade tillgångspriser. Finanspolitiken kan spela en ökad roll men stela ramverk och svaga statsfinanser gör att stimulansdosen ändå blir försiktig. I Sverige tyder sentimentsindikatorer på svag eller t o m fallande BNP i slutet av 2019 och början av 2020. Åter­hämtning för hushållens konsumtion och vändning för bostadsbyggandet talar dock för att BNP fortsätter växa under 2020. Tillväxten stärks 2021 när Sverige följer med internationell konjunktur uppåt. Fortsatt stark befolkningstillväxt bidrar till

SEB: Nordic Outlook: Short-term relief but long-term risks21.1.2020 07:00:00 CETPress release

Press release Stockholm, January 21, 2020 Nordic Outlook: Short-term relief but long-term risks Sweden: Below-trend growth, rising unemployment and key rate pause The world economy seems to have emerged from last year’s manufacturing slump. Growth is accelerating cautiously, but lingering political uncertainty and supply-side constraints are diminishing the power of the upturn. Central bank signals of low key interest rates for a lengthy period will provide support, but they also raise questions about long-term risks of debt build-up and spiralling asset prices. Fiscal policymakers can play an increased role, but because of rigid fiscal frameworks and weak government finances, the dose of stimulus will still be cautious. In Sweden, sentiment indicators point to weak or even falling GDP in late 2019 and early 2020, but a recovery in household consumption and a turnaround in residential construction suggest that the economy will keep expanding in 2020. Growth will speed up in 2021 as Swe

EVS Broadcast Equipment reports update of share buyback program20.1.2020 18:00:00 CETPress release

Publication on January 20, 2020, 6.00pm CET Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on October 24, 2018, took place between January 14, 2020 and January 17, 2020. Date Number of shares acquired Average price (EUR) Total (EUR) 14/01/2020 1,000 21.1750 21,175 15/01/2020 500 21.1250 10,563 16/01/2020 750 21.0833 15,812 17/01/2020 500 21.1000 10,550 As of January 17, 2020, and since the start of the buyback program, EVS has bought 324,282 shares at an average price of EUR 20,9751, representing in total EUR 6,801,832. After aforementioned transactions the total number of own shares amounts now to 402,930 shares as of January 17, 2020 (including 93,144 shares already held by the company before the start of the sha

NNIT A/S: 1/2020 NNIT releases preliminary figures for 2019 and outlook for 202020.1.2020 17:09:00 CETPress release

Company announcement 01/2020 NNIT releases preliminary figures for 2019 and preliminary guidance for 2020 In connection with reporting the collected consensus information back to analysts, the preliminary, unaudited figures were unfortunately disclosed by a mistake. Please find further information below. Revenue increase of 1.7% and an operating profit margin of 7.8% before restructuring costs (8.0% in constant currencies) in 2019. Performance highlights for the fourth quarter of 2019 and guidance: Revenue decreased by 2.7% in Q4 2019 compared to Q4 2018 driven by a 27% decline from the Novo Nordisk Group. This was partly countered by growth from international life sciences (35%), finance (24%), public (18%) and Danish life sciences (5.9%) Excluding business from Novo Nordisk Group revenue increased 13% (8.4% organic) in Q4 2019. The share of NNIT’s revenue from clients outside the Novo Nordisk Group increased to 70% in Q4 2019 from 61% in Q4 2018 Gross profit decreased by 13% in Q4 20